Tag Archives: ipo news

Acacia Communications Bolts, Giving Silent Tech IPO Market A Jolt

The tech IPO market remains in the doldrums, but it got a spark with Acacia Communications ( ACIA ), which turned in a strong debut on its first day of trading Friday. For its initial public offering, Acacia priced 4.5 million shares at $23 a share, the high end of its estimated range, raising $104 million. In afternoon trading in the stock market today , Acacia stock was above 31, up 35%, on volume of more than 3 million shares. The company makes chips that boost the speed and performance of optical communications networks used by cloud infrastructure operators and other content service providers. Its products include low-power digital signal processors that are application specific. It also makes silicon photonic chips that help facilitate data speeds of up to 400 gigabits per second, for use in data centers. It is also developing optical interconnect modules that will enable transmission speeds of 1,000 gbps and more. “We believe we are leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor,” the company said in its IPO prospectus . The Maynard, Mass.-based company has grown rapidly. Revenue rose 64% in 2015, to $239 million. It reported 2015 net income of $40.5 million, up from $13.5 million in 2014. First-quarter revenue rose 78% to $47.2 million, with net income of $14.6 million. Acacia has about 25 customers, of which the top five account for about 83% of revenue. Its largest customers are ADVA Optical Networking North America, ZTE Kangxun Telecom, Coriant, and Alcatel-Lucent, it says in its IPO prospectus. Competitors include  Cisco Systems ( CSCO ), Broadcom ( AVGO ), Finisar ( FNSR ) and Ciena ( CIEN ).  

First IPOs of 2016 BeiGene, Editas Medicine Surge On First Day

The first initial public offerings of 2016 arrived Wednesday with BeiGene ( BGNE ) and Editas Medicine ( EDIT ) both rising by double-digit percentages on their first trading day. Editas Medicine, a developer of gene editing therapies, raised $94 million by offering 5.9 million shares at 16, the low end of its 16-to-18 price range. The stock rose 13.8% to close at 18.20 in the stock market today . BeiGene, a China-based developer of cancer therapies that target a body’s immune system to fight cancer, raised $158 million by offering 6.6 million shares at 24, the high end of the range of its 22-to-24 range. BeiGene rose 18% to close at 28.32. They are the first U.S. listed IPOs since the Dec. 17 debut of Chinese peer-to-peer lender Yirendai ( YRD ). IPO research firm Ipreo said it was only the third time since 2001 that the new issuance market remained dormant during the month of January. Editas is described by the company as “a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes.” It uses a technology known as CRISPR, or clustered, regularly interspaced short palindromic repeats, which has the potential to achieve precise, directed changes in DNA. BeiGene is described as a “globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.” Image provided by Shutterstock .